Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal 2 malignancies worldwide. Altered metabolism is considered as one of the hallmarks of 3 cancer. Therefore, a better understanding of metabolic dysregulation in pancreatic 4 cancer could lead to the discovery of novel therapeutic targets. In the present study, we 5 investigated metabolic dysregulation and gene-metabolite networks in pancreatic Furthermore, our study demonstrated that integration of omics data provide a systems 10 level perspective of pancreatic cancer that could facilitate the development of novel 11 treatments for this disease. Results: 55 metabolites were consistently altered in tumors as compared with adjacent 10 nontumor tissues in a test cohort (N=33) and an independent validation cohort (N=31).
Translational Relevance
Furthermore, our study demonstrated that integration of omics data provide a systems 10 level perspective of pancreatic cancer that could facilitate the development of novel 11 treatments for this disease. PDAC cases is less than 6 months, and only 6% of patients survive 5 years after 9 diagnosis. The mortality rate has not improved significantly, due to late diagnosis and 10 resistance to available chemotherapy. Therefore, a better understanding of molecular 11 mechanisms of disease progression and discovery of novel therapeutic targets are 12 desperately needed to improve outcomes in patients with PDAC.
13
Genetic alterations have been extensively characterized in pancreatic cancer. The development of pancreatic cancer has also been linked to abnormal glucose 2 metabolism which is induced by long-term type 2 diabetes, a known risk factor for 3 pancreatic cancer (6). Metabolites are central in intermediary metabolism, and they 4 provide substrates for biological processes, and have an active role in regulating cell 5 cycle, proliferation and apoptosis (7). Recently, there has been an increased interest in an innovative way to reveal the complex regulatory networks involving genes and 13 metabolic pathways in cancers (9, 10).
14
In the present study, we have performed global metabolite profiling analysis in 15 two independent cohorts of PDAC cases to identify critical metabolite alterations that 16 may contribute to the progression of pancreatic cancer. We then searched for gene 17 surrogates that were significantly correlated with the key metabolites using transformed into an adjacency matrix using a power function, which resulted in a 9 weighted network (14). WGCNA defines modules as a group of densely interconnected 10 molecules with high topological overlap in weighted network analysis. For each data set,
11
we used average linkage hierarchical clustering with a dynamic tree-cutting algorithm to 12 identify modules on the basis of the topological overlap dissimilarity measure (15).
13

Ingenuity Pathways Analysis
14
Canonical pathway analysis identified the pathways from the Ingenuity Pathways
15
Analysis library of canonical pathways that were most significant to the data set. The 16 association between the data set and the canonical pathway was measured in 2 ways:
17
(i) The statistical significance: Fischer's exact test was used to calculate a p-value 18 determining the probability that the association between the genes in the data set and any sample with a gene cycle value greater than 36 was considered of poor quality and 1 removed. All the primers for qRT-PCR in the present study were purchased from 2 Applied Biosystems (Table S1) . 
15
MTT assay
16
Cells were seeded in 96-well plates (3,000-5000 cells/well) and incubated for 2- 
Results
10
Metabolomics of PDAC
11
The characteristics of the patients with PDAC in a test cohort (N=33) and a 12 validation cohort (N=31) are shown in Table S1 . The two cohorts were similar in TNM 13 staging, resection margin status, grade and cancer-specific mortality (P=0.76, Kaplan-
14
Meier log rank) with 1-year survival rate of 50.8% for the test cohort and 51% for the 15 validation cohort.
16
Metabolite profiling was performed using liquid and gas chromatography coupled (Table S2) . Weighted network analysis identified a unique set of fatty acids that are co-1 regulated in PDAC. 2 We constructed coexpression networks using the 55 metabolite profiling data in 2 3 independent cohorts. According to recently described methodology (14), the 4 connectivity (k) was determined for all metabolites in the network by taking the sum of 5 their connection strengths (coexpression similarity) with all other nodes in the network.
6
To identify modules of highly co-regulated metabolites, we used average linkage 
16
Because of the indicated importance of hubs in the network, we ranked 17 metabolites within turquoise module (Table S3) based on their intramodular connectivity 18 to identify module hubs (Table 1) . Eight metabolites with high connectivity (IMconn > 6) 19 in the turquoise module represented the main hubs in both test and validation cohorts. Interestingly, this set of highly co-regulated hub metabolites are all free fatty acids,
21
suggesting that fatty acid metabolism may be significantly altered in PDAC. Table S4 ). (Table 1) .
9
To validate the association of these lipases with the set of 8 fatty acids identified and consistently all 8 fatty acids were also decreased in tumors from both cohorts 15 (Table 2) . Particularly, qRT-PCR data in the validation cohort showed ~100-to 1000- There's no significant association between 8 fatty acids and cancer-specific 8 mortality in both cohorts of PDAC cases (data not shown). We then tested whether the 
and formation of gallstones, bladder problems and cystitis. Therefore, pancreatic lipase 1 supplements are used to treat PNLIP deficiency diseases (49). However, the role of 2 PNLIP in pancreatic cancer remains unknown. In this study, we have shown striking 3 decreases (>100 fold) in the gene expression of all four lipases including PNLIP in 4 pancreatic tumors, and consistently immunohistochemical staining on paraffin sections 5 also showed that PNLIP protein level is lower in pancreatic ductal carcinomas as 6 compare to normal ducts ( Figure S3 ). In addition, our study also provided the first 7 evidence that a lower expression of PNLIP is associated with poor outcome in PDAC.
8
In summary, we have used a systems biology approach and identified an altered 
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